PIK3CA and cancer: More generally, the diagnostic and therapeutic benefits of combined, comprehensive genomic and non-genomic analyses were recently demonstrated in patients with rare cancers [49], and are worth considering in the context of breast and other cancers where PI3K pathway alterations feature prominently [3].